CibusCBUS
Market Cap: $103M
About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Employees: 183
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
10% more funds holding
Funds holding: 48 [Q1] → 53 (+5) [Q2]
6.54% more ownership
Funds ownership: 29.57% [Q1] → 36.11% (+6.54%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
42% less capital invested
Capital invested by funds: $139M [Q1] → $81.4M (-$58M) [Q2]
84% less call options, than puts
Call options by funds: $119K | Put options by funds: $732K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Canaccord Genuity Austin Moeller 22% 1-year accuracy 6 / 27 met price target | 372%upside $21 | Buy Maintained | 12 Aug 2024 |
Alliance Global Partners Matthew Venezia 0% 1-year accuracy 0 / 1 met price target | 462%upside $25 | Buy Initiated | 29 Jul 2024 |
Canaccord Genuity Austin Moeller 22% 1-year accuracy 6 / 27 met price target | 394%upside $22 | Buy Assumed | 19 Jul 2024 |